Guest guest Posted July 31, 2004 Report Posted July 31, 2004 > JustSayNo > Thu, 29 Jul 2004 22:15:28 -0400 > [sSRI-Research] Dr. Andrew Mosholder's > suppressed report [to FDA on Feb. 2nd] is posted > {URL for Report is toward the end of this article} > > Dr. Andrew Mosholder is but the most recent example > to come to light, of an > FDA medical officer whose expert analysis and > recommendations were > suppressed by the agency because the recommendations > might affect the > financial interests of a drug manufacturer. > > Dr. Mosholder was asked to analyze the Paxil data in > Sept. 2003, after the > British regulatory agency examined the clinical > trial data and found a > suicidal risk for children / adolescents prescribed > Paxil / paroxetine. The > British issued a prohibition on the use of Paxil for > children (June 2003). > > Dr. Mosholder then analyzed the suicidal behavior > data submitted by drug > manufacturers of 9 different antidepressants to the > FDA from 22 randomized, > placebo-controlled clinical trials. In these trials, > 4,250 children / > adolescents participated: 2,298 were given an active > drug, and 1,952 were > given a placebo. > > Dr. Mosholder found that 108 child-patients suffered > suicide-related events: > 74 were on active drug, and 34 on placebo. Of > these, 78 were serious > adverse events--54 occurred in children taking an > active drug, compared to > 24 on placebo. Children on an antidepressant were at > greater than twofold > increased risk of drug-induced suicidal behavior. > > Inasmuch as the drugs--with the possible exception > of Prozac*--have failed > to demonstrate a benefit in clinical trials, these > serious risks are not > offset by any scientifically proven benefit for > children. Therefore, a > minimal precautionary action would require prominent > warnings to physicians > and families. > > Dr. Anne Trontell, Director, Div. Of > Neuropharmacological Drug Products, and > Dr. Mark Avigan, Director, Div. Drug Risk > Evaluation, concurred with Dr. > Mosholder's analysis and conclusions, but disagreed > that physicians and > families should be warned about these risks. > > Dr. Mosholder's medically responsible, science-based > recommendation: > > " Given the strength of the association shown by the > present data, the > clinical importance of the apparent effect...and the > fact that the > additional analyses are likely to take several more > months to complete while > considerable numbers of pediatric patients are being > exposed to these drugs, > I favor an interim risk management plan regarding > the use of these drugs in > the pediatric population. This might be of value to > physicians, patients > and families who are faced with the need to make a > decision regarding > pharmacotherapy at the present time. Specifically, I > propose a risk > management strategy directed at discouraging the > off-label pediatric use of > antidepressant drugs, particularly the use of drugs > other than fluoxetine in > the treatment of pediatric MDD [major depressive > disorder]. Conceivably, > this might include discouraging the initiation of > treatment of drug-naïve > pediatric MDD patients with off-label drugs, in the > absence of some > over-riding clinical consideration. " > > Dr. Mosholder's embargoed report and the > accompanying Trontell and Avigan > memos are posted on the AHRP website at: > http://www.ahrp.org/risks/SSRImosholder/index.html > > > Of note: FDA's chief counsel, Daniel Troy, is the > architect of the > administration's aggressive intervention in court on > the side of drug and > medical device manufacturers. Troy is one of over > 100 top government > regulators appointed by the Bush administration, who > were identified as > advocates for the industries they are supposed to > regulate. > > See: Anne Mulkern, When Advocates Become Regulators. > Denver Post, May 14, > 2004. http://www.ahrp.org/infomail/04/05/24.html > > See also: Jeanne Lenzer, FDA's counsel accused of > being too close to drug > industry BMJ, July 24, 2004 > > http://bmj.bmjjournals.com/cgi/reprint/329/7459/189?maxtoshow= & HITS=10 & hits= > 10 & RESULTFORMAT= & fulltext=Troy & searchid=1090843404662_4568 & stored_search= & FI > RSTINDEX=0 & volume=329 & issue=7459 > > Examples refuting the basis of FDA's pre-emption > argument: FDA's decisions > about drug safety are not always based on scientific > evidence. All too often > FDA decisions result in preventable deaths: > > REZULIN: > http://www.latimes.com/news/nation/reports/fda/lat_fda001220.htm > > PROPULSID: > http://www.latimes.com/news/nation/reports/fda/lat_propulsid001220.htm; > webmd.com/content/article/22/1728_55973 > > FEN-PHEN: http://www.redux-settlement.com/ > Phenylpropanolamine (PPA): > http://www.latimes.com/news/nationworld/nation/la-na-ppa28mar28-1,1,2552623. > htmlstory?coll=la-home-left1 > > RISPERDAL (risperidone); ZYPREXA (olanzapine): > http://www.ahrp.org/infomail/0702/12b.html > > *It should be noted that in Dec. 2003, Eli Lilly, > manufacturer of Prozac, > issued a label change in the UK stating, Prozac is > NOT recommended for > children. See: > http://www.ahrp.org/risks/ProzacKids1203.html ; > > Contact: Vera Hassner Sharav > Tel: 212-595-8974 > e-mail: veracare > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.